Trial Profile

Phase IIb dose-ranging study of GRC 17536 in patients with neuropathic pain

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 23 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ISC 17536 (Primary)
Indications Diabetic neuropathies; Neuropathic pain
Focus Therapeutic Use
Sponsors Glenmark Pharmaceuticals Ltd

Most Recent Events

12 Nov 2019 According to an Ichnos Sciences media release, this study is expected to start in 2020.
02 Oct 2014 New trial record
17 Sep 2014 Glenmark plans to file for this study at the end of the 2014 financial year, according to a media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com